Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study
Sign Up to like & getrecommendations! Published in 2021 at "Cancers"
DOI: 10.3390/cancers14010207
Abstract: Simple Summary This prospective, multicenter study aimed to investigate the efficacy and safety of a front-line treatment with the ibrutinib and rituximab combination in 146 unfit patients with chronic lymphocytic leukemia (CLL). We observed an… read more here.
Keywords: rituximab combination; ibrutinib rituximab; treatment; unfit patients ... See more keywords